Ensysce Biosciences, Inc. (ENSC) Stock Price & Analysis
Ensysce Biosciences, Inc. (ENSC) — MoonshotScore 20/100 (Weak band), calculated Nov 18, 2026. Price $0.3699 (-4.91%), as of the Nov 18, 2026 trading session; market cap $7.20M.
Educational signal · not a buy or sell recommendation · How to read this
Ensysce Biosciences, Inc. · ENSC · NASDAQ
Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing novel pain relief and overdose protection technologies. Their primary focus is on creating abuse-resistant and overdose-resistant opioid prodrugs.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Ensysce Biosciences (ENSC)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a strained balance sheet and stalling growth — broad distress, a capital-preservation call, not a value entry. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Fair; Growth Durability: Shrinking; Momentum: Quiet.
- EPS beat 0 of the last 4 reports
- Altman Z -9.15 · Piotroski F 4
Holding back: weak fundamentals, soft growth
Helping: an attractive price
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 19 | Weak | |
| 18 | Weak | |
| 19 | Weak | |
| 19 | Weak | |
| 20 | Weak | |
| 20 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.3699 | |
| Change on the day | -4.91% | |
| 52-week range | $0.23 – $2.16 | |
| Market capitalisation | $7.20M | — |
| Price / earnings (trailing) | -0.22 | |
| Shares traded on the day | 130.0K |
Price & events
Other perspectives
Council score for Ensysce Biosciences (ENSC): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Ensysce Biosciences (ENSC), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Ensysce Biosciences, Inc. (ENSC) is listed on NASDAQ. It employs 9 people and is led by D. Lynn Kirkpatrick. The market values it at $7.20M.
What do the latest results show for Ensysce Biosciences (ENSC)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2026 | $2M | -$82M | -$4.51 (diluted) |
| Q2 FY2026 | $1M | -$3M | -$0.20 (diluted) |
| Q1 FY2026 | $0 | -$4M | -$0.52 (diluted) |
| Q4 FY2025 | $2M | -$3M | -$0.11 (diluted) |
What are the financial strengths and risks for Ensysce Biosciences (ENSC)?
Short answer · as of
The MoonshotScore pillars rate an attractive price as strengths. What is holding it back is weak fundamentals, soft growth. The distress and quality screens read Altman Z -9.15 · Piotroski F 4. Trailing ratios: current ratio 8.02.
Data-derived red flags
- Listing risk — at $0.3699 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -9.15 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
How does Ensysce Biosciences compare with its peers?
Short answer
Ensysce Biosciences's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.02 Nov 18, 2026 | $255M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.96 Nov 18, 2026 | $186M | 69 5-pillar Nov 18, 2026 | |
| $12.48 Nov 18, 2026 | $884M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $8.32 Nov 18, 2026 | $813M | 63 5-pillar Nov 18, 2026 | |
| $3.29 Nov 18, 2026 | $505M | 60 5-pillar Nov 18, 2026 | |
| Ensysce Biosciences (ENSC) — this page | $0.3699 | $7.20M | 20 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 4
- Purchases
- 6
- Sales
- 0
- Other transactions
- 6
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held ENSC in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported ENSC in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Ensysce Biosciences (ENSC)?
Ensysce Biosciences Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the ENSC research dossier (written Jun 1, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for ENSC?
ENSC carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company focused on developing novel pain relief and overdose protection technologies.
Is ENSC a good stock to buy?
Stock Expert AI does not rate ENSC buy, sell or hold. Ensysce Biosciences, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the ENSC stock price today?
The last price recorded for Ensysce Biosciences, Inc. (ENSC), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the main risks for ENSC?
The main risks for Ensysce Biosciences, Inc. include the inherent risks associated with clinical-stage pharmaceutical companies, such as the possibility of unsuccessful clinical trial outcomes and failure to obtain regulatory approval from the FDA. The company's high cash burn rate and dependence on securing additional funding also pose financial risks.
What are the key factors to evaluate for ENSC?
Ensysce Biosciences, Inc. (ENSC) holds a MoonshotScore in the low range. Ensysce Biosciences is a clinical-stage pharmaceutical company focused on developing abuse-resistant and overdose-resistant opioid prodrugs. Not financial advice.
How frequently does ENSC data refresh on this page?
ENSC's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven ENSC's recent stock price performance?
Ensysce Biosciences, Inc. (ENSC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative TAAP and MPAR technology platforms. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ENSC overvalued or undervalued right now?
Ensysce Biosciences, Inc. (ENSC) is loss-making, so its trailing P/E (listed under Price & valuation) is negative and not usable for valuation — lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of ENSC?
Fractional-share availability for Ensysce Biosciences, Inc. (ENSC) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Jun 1, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 7 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com